Cardiovascular highlights from non-cardiology journals

Lindsay, Alistair
April 2013
Heart;Apr2013, Vol. 99 Issue 8, p586
Academic Journal
The article focuses on a clinical trial which found that increased pain-free and maximum walking times is associated with angiotensin-converting enzyme inhibitor ramipril, which improves symptoms of intermittent claudication. It is concluded that postoperative morbidity, mortality and resource utilization is improved with the implementation of a conservative blood transfusion strategy.


Related Articles

  • ACE Inhibitors to Prevent Cardiovascular Events in High-Risk Patients. VandeKieft, Gregg K. // Journal of Family Practice;Apr2000, Vol. 49 Issue 4, p373 

    The article asserts that the use of angiotensin-converting-enzyme (ACE) inhibitor in therapy lessen the risks of cardiovascular events in patients. It presents a study regarding the effectivity of ACE inhibitors in high-risk patients who do not have left ventricular dysfunction or heart failure....

  • 'Untitled' Fitchett, David // CMAJ: Canadian Medical Association Journal;6/24/2003, Vol. 168 Issue 13, p1646 

    Relates the therapeutic benefits of ramipril. Overview of the Heart Outcomes Prevention Evaluation (HOPE) study which showed the reduction of cardiovascular mortality; Study which revealed the efficacy of the drug; Factor attributed to the sales increase of the drug after publication of the...

  • Ramipril and telmisartan: Equally effective for patients at high risk of vascular events?  // Journal of Family Practice;Jul2008, Vol. 57 Issue 7, p443 

    The article reports on the efficacy of angiosten-converting enzyme inhibitor (ACEI) ramipril and angiosten receptor blocker (ARB) telmisartan in treating patients with high risk of cardiovascular diseases. Results of a clinical study show that ramipril and telmisartan are both effective...

  • Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure. Demers, Catherine; McMurray, John J. V.; Swedberg, Karl; Pfeffer, Marc A.; Granger, Christopher B.; Olofsson, Bertil; McKelvie, Robert S.; Östergren, Jan; Michelson, Eric L.; Johansson, Peter A.; Wang, Duolao; Yusuf, Salim // JAMA: Journal of the American Medical Association;10/12/2005, Vol. 294 Issue 14, p1794 

    Context Angiotensin-converting enzyme (ACE) inhibitors reduce the risk of myocardial infarction (MI), but it is not known whether angiotensin receptor blockers have the same effect. Objective To assess the impact of the angiotensin receptor blocker candesartan on MI and other coronary events in...

  • Spotlight on Ramipril in the Prevention of Cardiovascular Outcomes. Gregory T. Warner; Caroline M. Perry // American Journal of Cardiovascular Drugs;Mar2003, Vol. 3 Issue 2, p113 

    Ramipril (Altace®), an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which is rapidly hydrolyzed after absorption to the active metabolite ramiprilat. Earlier trials have shown that ACE inhibitors, when given to patients with low ejection fractions, have reduced the relative...

  • Higher resting heart rate may predict CV death.  // Clinical Advisor;Feb2012, Vol. 15 Issue 2, p16 

    The article offers information on the research which reveals that increase in resting heart rate (RHR) in people with risk of death from ischemic heart disease without known cardiovascular disease (CVD) has no general mortality benefit.

  • The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. Tu, Karen; Mamdani, Muhammad M.; Jacka, Robert M.; Forde, Natalie J.; Rothwell, Deanna M.; Tu, Jack V. // CMAJ: Canadian Medical Association Journal;3/4/2003, Vol. 168 Issue 5, p553 

    Background: The Heart Outcomes Prevention Evaluation (HOPE), a Canadian-led, multicentre, randomized controlled trial, demonstrated the effectiveness of the ACE inhibitor ramipril in the secondary prevention of cardiovascular disease in patients who were at high risk for cardiovascular events...

  • Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective. Schädlich, Peter K.; Brecht, Josef Georg; Rangoonwala, Badrudin; Huppertz, Eduard; Schädlich, Peter K // PharmacoEconomics;2004, Vol. 22 Issue 15, p955 

    Background: In the HOPE (Heart Outcomes Prevention Evaluation) trial, ramipril (compared with placebo) significantly reduced cardiovascular death and all-cause mortality as well as the incidence of costly cardiovascular events, such as myocardial infarction, revascularisation,...

  • More help for patients with less severe heart failure. Bossenbroek, Kelly; Mounsey, Anne L.; Ewigman, Bernard // Journal of Family Practice;Aug2011, Vol. 60 Issue 8, p482 

    The article focuses on the benefits of mineralocorticoid-receptor antagonists in reducing hospitalizations due to heart failure and cardiovascular and all-cause mortality. It presents a case study of a 56-year old man who had a stable condition after taking angiotensin-converting enzyme...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics